ZRSR2 overexpression is a frequent and early event in castration-resistant prostate cancer development

BACKGROUND: Androgen deprivation therapy (ADT) remains the leading systemic therapy for locally advanced and metastatic prostate cancers (PCa). While a majority of PCa patients initially respond to ADT, the durability of response is variable and most patients will eventually develop incurable castra...

Descripción completa

Detalles Bibliográficos
Autores principales: He, Haiqing, Hao, Jun, Dong, Xin, Wang, Yu, Xue, Hui, Qu, Sifeng, Choi, Stephen Yiu Chuen, Ci, Xinpei, Wang, Yong, Wu, Rebecca, Shi, Mingchen, Zhao, Xiaokun, Collins, Colin, Lin, Dong, Wang, Yuzhuo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8384624/
https://www.ncbi.nlm.nih.gov/pubmed/33568749
http://dx.doi.org/10.1038/s41391-021-00322-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8384624/
https://www.ncbi.nlm.nih.gov/pubmed/33568749
http://dx.doi.org/10.1038/s41391-021-00322-7

Ejemplares similares